VRDN240816C12500
- 4.50
- 0.000.00%
Viridian Therapeutics Newsroom
Buy Rating for Viridian Therapeutics on VRDN-001 Clinical Advancements and Market Potential
Viridian Therapeutics Analyst Ratings
Buy Rating for Viridian Therapeutics Amidst Promising Thyroid Eye Disease Drug Trials
Buy Rating Affirmed for Viridian Therapeutics Amid Promising TED Treatment Advancements
Viridian Therapeutics Analyst Ratings
Wolfe Research Initiates Coverage on Viridian Therapeutics With Outperform Rating, $29 Price Target
Viridian Therapeutics Analyst Ratings
Viridian Therapeutics (VRDN) Gets a Buy From Stifel Nicolaus
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Viridian Therapeutics Amidst Accelerated Clinical Progress and Market Expansion Potential
HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27
Viridian Therapeutics Analyst Ratings
Buy Rating Affirmed for Viridian Therapeutics on Strong Clinical Trials and Promising Drug Prospects
Viridian Therapeutics Analyst Ratings
Buy Rating Affirmed for Viridian Therapeutics Amidst Strong Pipeline Progress and Solid Financial Standing
Buy Rating Affirmed for Viridian Therapeutics on Promising VRDN-001 Trials and Strong Financial Outlook
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)